For use in dogs only. Do not use in cats. Do not use in dogs with known tympanic membrane perforation. Verify the tympanic membrane is intact prior to administration. KLENTZ™ is contraindicated in dogs with known or suspected hypersensitivity to florfenicol, terbinafine hydrochloride, or mometasone furoate. KLENTZ™ should be administered by veterinary personnel. Wear eye protection when administering KLENTZ™ and restrain the dog to minimize post application head shaking. Splatter may occur if the dog shakes its head following administration. KLENTZ™ may cause eye injury and irritation. Do not administer orally. Use with caution in dogs with impaired hepatic function. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment. Owners should be aware that adverse reactions may occur following administration of KLENTZ™ and should be instructed to observe the dog for signs such as ear pain and irritation, vomiting, head shaking, head tilt, incoordination, eye pain and ocular discharge. Owners should also be informed that splatter may occur if the dog shakes its head following administration of KLENTZ™ which may lead to ocular exposure. Eye injuries, including corneal ulcers, have been reported in humans and dogs associated with head shaking and splatter following administration. Owners should be careful to avoid ocular exposure. Not for use in humans. Keep this and all drugs out of reach of children. For complete safety information, please see the KLENTZ™ package insert.